Epithelial-Specific Methylation Marker: A Potential Plasma Biomarker in Advanced Non-small Cell Lung Cancer

Background: Under physiological conditions, leukocytes contribute the majority of circulating DNA in plasma. Therefore, detection of methylation at the SHP-1 promoter 2 (SHP1P2) in plasma, which represents epithelial tumor-derived circulating nucleic acids, may serve as a potential noninvasive biomarker for non-small cell lung cancer (NSCLC). Materials and Method: A quantitative polymerase chain reaction-based assay was used to determine the level of SHP1P2 methylation in plasma. Blood samples were prospectively collected from 58 patients with advanced NSCLC, 20 patients with early NSCLC, and 52 healthy volunteers. Results: Most of the healthy volunteers exhibited undetectable levels of SHP1P2 methylation. In contrast, the pretreatment levels of SHP1P2 methylation in the patients with NSCLC were readily detectable, with a median value of 770 pg ml−1 (0–26,500 pg ml−1), which was significantly higher than that of the healthy controls. Furthermore, the patients with advanced NSCLC who presented baseline levels of SHP1P2 methylation of less than 700 pg ml−1 exhibited enhanced median progression-free survival (5.2 versus 2.6 months, p = 0.009) and improved median overall survival (12.6 versus 7.6 months, p = 0.01) compared with patients who exhibited SHP1P2 methylation levels greater than 700 pg ml−1. From a multivariate analysis, the levels of SHP1P2 methylation were significantly associated with survival rates in advanced NSCLC. Conclusion: Measurement of the level of SHP1P2 methylation in plasma serves as a potential noninvasive biomarker for the prognostic assessment of patients with lung cancer. This biomarker can be used to develop risk-adaptive treatments for patients with lung cancer.

[1]  Walter Weder,et al.  Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Chein-Hui Hung,et al.  Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma , 2007, Cancer.

[3]  S. Leung,et al.  Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Simon,et al.  Smoking Induces Long-Lasting Effects through a Monoamine-Oxidase Epigenetic Regulation , 2009, PloS one.

[5]  S. Davis,et al.  Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate , 2010, Oncogene.

[6]  U. Pastorino,et al.  Detecting lung cancer in plasma with the use of multiple genetic markers , 2004, International journal of cancer.

[7]  A. Mutirangura,et al.  SHP-1 promoter 2 methylation in normal epithelial tissues and demethylation in psoriasis , 2006, Journal of Molecular Medicine.

[8]  Yau-Huei Wei,et al.  Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. , 2004, The New England journal of medicine.

[9]  H. Mulcahy,et al.  Detection of Circulating Tumour DNA in the Blood (Plasma/Serum) of Cancer Patients , 2004, Cancer and Metastasis Reviews.

[10]  U. Pastorino,et al.  Quantification of free circulating DNA as a diagnostic marker in lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. C. Tsang,et al.  Circulating nucleic acids in plasma/serum , 2007, Pathology.

[12]  C. Lam,et al.  Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. , 2002, Clinical chemistry.

[13]  A. Theamboonlers,et al.  Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  D. Sidransky,et al.  Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. , 2002, Cancer research.

[15]  M. Stroun,et al.  Neoplastic characteristics of the DNA found in the plasma of cancer patients. , 1989, Oncology.

[16]  J. Herman,et al.  Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. , 1999, Cancer research.

[17]  S. Leung,et al.  Persistent Aberrations in Circulating DNA Integrity after Radiotherapy Are Associated with Poor Prognosis in Nasopharyngeal Carcinoma Patients , 2008, Clinical Cancer Research.

[18]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[19]  H. Mulcahy,et al.  Circulating nucleic acids in plasma and serum as a noninvasive investigation for cancer: Time for large‐scale clinical studies? , 2003, International journal of cancer.

[20]  R. Stocco,et al.  Human protein tyrosine phosphatase 1C (PTPN6) gene structure: alternate promoter usage and exon skipping generate multiple transcripts. , 1995, Genomics.

[21]  R. Swaminathan,et al.  Overview of Circulating Nucleic Acids in Plasma/Serum , 2008, Annals of the New York Academy of Sciences.

[22]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[23]  L. Mariani,et al.  Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. , 2001, Cancer research.

[24]  R. Turner,et al.  Assessment of Methylation Events during Colorectal Tumor Progression by Absolute Quantitative Analysis of Methylated Alleles , 2007, Molecular Cancer Research.

[25]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.